Search

439 results for "lecanemab".

Research summaries 393

Showing the best 200 of 393, 1–10, page 1 of 20. Filter these by subject, year and score in the research library →

1. Exploring the efficacy and safety of lecanemab in the management of early Alzheimer's disease: A systematic review of clinical evidenceResearch summary

   Research summaries · alzhub.org/study/exploring-the-efficacy-and-safety-of-lecanemab-in-the-management-of-40232258

   … functional impairment. Lecanemab has shown safety and efficacy in clinical trials.ObjectiveThis review aims to understand the clinical evidence of lecanemab's effectiveness and safety in managing early AD.MethodsA systematic …

2. Lecanemab-Monoclonal Antibodies for the Treatment of Early Alzheimer's DiseaseResearch summary

   Research summaries · alzhub.org/study/lecanemab-monoclonal-antibodies-for-the-treatment-of-early-alzheimer-42890315

   Objective Review the pharmacology, efficacy, and safety of lecanemab, a humanized immunoglobulin gamma 1 (IgG1) monoclonal antibody, for the treatment of early Alzheimer's disease (AD). Data sources Comprehensive search of …

3. Use of lecanemab for the treatment of Alzheimer's disease: A systematic reviewResearch summary

   Research summaries · alzhub.org/study/use-of-lecanemab-for-the-treatment-of-alzheimer-s-disease-a-38867460

   Purpose The US Food and Drug Administration authorized lecanemab for the therapeutic use of Alzheimer's disease (AD) in January 2023. To assess the effectiveness and safety of lecanemab in treating AD, we thoroughly examined the …

4. Anti-Amyloid Monoclonal Antibodies in Early Alzheimer Disease: Lecanemab and DonanemabResearch summary

   Research summaries · alzhub.org/study/anti-amyloid-monoclonal-antibodies-in-early-alzheimer-disease-42784125

   … occurred in 12.6% of lecanemab-treated and 24.0% of donanemab-treated participants in the pivotal trials, with higher risk in APOE ε4 carriers. Extensions and biomarker analyses suggest persistent biological effects but are less …

5. Monoclonal therapy with lecanemab in the treatment of mild Alzheimer's disease: A systematic review and meta-analysisResearch summary

   Research summaries · alzhub.org/study/monoclonal-therapy-with-lecanemab-in-the-treatment-of-mild-alzheimer-39638097

   … plaques in the brain. Lecanemab (BAN2401), a humanized IgG1 monoclonal antibody, binds with high affinity to Amyloid-β protofibrils. It is the first monoclonal antibody for Alzheimer's disease to receive full FDA approval. This …

6. Novel anti-amyloid-beta (Aβ) monoclonal antibody lecanemab for Alzheimer's disease: A systematic reviewResearch summary

   Research summaries · alzhub.org/study/novel-anti-amyloid-beta-a-monoclonal-antibody-lecanemab-for-alzheimer-37902139

   The FDA approved lecanemab for Alzheimer's disease in January 2023 which acts as a novel disease-modifying anti-amyloid-beta (Aβ) human monoclonal antibody and is administered intravenously. Based on the clinical trials included …

7. Lecanemab QuestionsResearch summary

   Research summaries · alzhub.org/study/lecanemab-questions-38484213

   … controlled trial of lecanemab, reporting the efficacy of the drug in slowing the progression of early Alzheimer disease, quickly led to approval by the FDA and widespread acceptance of lecanemab treatment. However, there are a …

8. Regulatory, clinical, and post-marketing challenges of lecanemab for Alzheimer's disease: insights from real-world dataResearch summary

   Research summaries · alzhub.org/study/regulatory-clinical-and-post-marketing-challenges-of-lecanemab-for-41787137

   Four regulatory agencies have approved lecanemab through different pathways, each requiring confirmation of amyloid pathology and careful assessment of ARIA risk, particularly in Apolipoprotein E (ApoE) ε4 homozygotes. Notable …

9. Safety profiles of lecanemab: A systematic review and meta-analysis of randomized controlled trials and real-world evidenceResearch summary

   Research summaries · alzhub.org/study/safety-profiles-of-lecanemab-a-systematic-review-and-meta-analysis-of-41478817

   Background Safety profiles of lecanemab, an anti-amyloid-β antibody for the treatment of early Alzheimer's disease (AD), remain uncertain and may vary between randomized controlled trials (RCTs) and real-world evidence (RWE) …

10. Efficacy and safety of lecanemab monoclonal antibody in the treatment of mild to moderate Alzheimer's disease: a systematic review and meta-analysisResearch summary

    Research summaries · alzhub.org/study/efficacy-and-safety-of-lecanemab-monoclonal-antibody-in-the-treatment-42865480

    … fixed-effect model, lecanemab treatment significantly improved cognitive performance on ADCOMS (SMD -0.1999, 95% CI [-0.2831, -0.1167], I 2 = 0%, P < 0.00001), CDR-SB (SMD -0.1853, 95% CI [-0.2683, -0.1024], I 2 = 0%, P < …

How this search works

There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.

One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.

31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.